Hydroxyurea (NSC-32065)

Catalog No.S1896 Synonyms: NCI-C04831, Hydroxycarbamide

For research use only.

Hydroxyurea (NSC-32065, NCI-C04831, Hydroxycarbamide) is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy. Hydroxyurea is used to treat HIV infection.

Hydroxyurea (NSC-32065) Chemical Structure

CAS No. 127-07-1

Selleck's Hydroxyurea (NSC-32065) has been cited by 28 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description Hydroxyurea (NSC-32065, NCI-C04831, Hydroxycarbamide) is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy. Hydroxyurea is used to treat HIV infection.
Targets
ribonucleoside diphosphate reductase [1]
In vitro

hydroxyurea can inhibit HIV-1 replication. In vitro experiments have shown that the 90% inhibitory concentration (IC90) of hydroxyurea for laboratory strains of HIV-1 in activated PBMC is 0.4 mM. Hydroxyurea was also found to be synergistic with the nucleoside reverse transcriptase inhibitor didanosine and to inhibit HIV-1 replication in activated PBMC; this inhibition may be due to a reduction in deoxynucleoside triphosphate pool sizes. Hydroxyurea has been shown to sensitize didanosine-resistant mutants[1][2].hydroxyurea has demonstrated activity in the treatment of sickle cell anemia by increasing the production of fetal hemoglobin, which reduces hemolysis in patients with this disease. Hydroxyurea exerts its cytostatic effect through inhibition of ribonucleotide reductase—the rate-limiting enzyme responsible for the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis. As a result, cellular division is arrested in the S phase[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 Leukemia cells MnXsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLIWFREd26lZX70doF1cW:wIILldZVqemWmIH\vdkA2OCViaX7obYJqfGmxbjDv[kBk\WyuIHfyc5d1cCBqTEGyNVAhVGW3a3XtbYEqNCCLQ{WwQVIyNjN5OU[g{txO M2PpW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUG1NlAoRjJ7OUG1NlA9N2F-
P388 leukemic cell M{LVTnBzd2yrZnXyZZRqd25iYYPzZZk> M1vTV|I1NTR6IHi= MnnZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgc4Yh[2:vcH;1coQh\XiycnXzd4VlKGG|IHPvcoNmdnS{YYTpc44hfGijdDDpcohq[mm2czC1NEUhd2ZiZ4Lve5RpKG:oIGCzPFghdGW3a3XtbYMh[2WubDDzeZNx\W6|aX;uJIZzd21iMkSgeI8hPDhiaIKgZYZ1\XJiY3;tdI92dmRiYXTkbZRqd25uIFnDOVA:OzJizszN MojIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOUO3Nkc,OjdyOUO3Nlww[T5?
L1210 M1KwfGZ2dmO2aX;uJIF{e2G7 NWrBUlVkPDhiaB?= MorCRYN1cX[rdImgZYdicW6|dDDjeYx1fXKnZDDMNVIyOCCuZYXr[Y1q[yClZXzsd{B4[XNiZHX0[ZJucW6nZDDpckB3cXS{bzygZYZ1\XJiNEigbEBw\iCrbnP1ZoF1cW:wLjDDc41xd3WwZDDkc5NmKHSqYYSgZ4F2e2W|IEG2JEUhcW6qaXLpeIlwdiC5YYOgdoVxd3K2ZXSsJGlFOTZiPTCxMlk6KM7:TT6= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek83OzF7N{CyK|43OzF7N{CyQE9iRg>?
U373-MAGI MUTGeY5kfGmxbjDhd5NigQ>? NEe4[oY2ODBidV2= NXLzUHczOiCqcoO= M33M[nBwfGWwdHnheIlwdiCxZjC1MWF7[S2FLXnu[JVk\WRiYX70bZZqemGuIHHjeIl3cXS7IHHnZYlve3RiVmPWMWcheHOndXTveJlx\WRiSFnWMVEhVkx2LUOgbY5n\WO2ZXSgbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy|IHHzd4V{e2WmIHHzJFUuSXqjLVOgSWM2OCCjdDC1NFAhfU1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSB3LVH6ZU1EKGGmZHn0bY9vKG[xcjCyJIhzeyCjbnSgd5Vje2WzdXXueEB3cXKjbDDpcoZm[3Srb36gcYVieyxiRVO1NEA:KDJ3Lkig{txONg>? M1j1d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
Burkitt's lymphoma cells MWjGeY5kfGmxbjDhd5NigQ>? NYX3OGdtUW6qaXLpeIlwdiCxZjDbNVREZS2leYTp[Ilv\SCrbnPvdpBwemG2aX;uJIlvfG9iRF7BJIlvKEK3cnvpeJQoeyCueX3wbI9u[SClZXzsd{whUUN3MDC9JFM4NjF3IN88UU4> NHricnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUSwOVY2Oyd-MUG0NFU3PTN:L3G+
U373-MAGI NHXRUVJCdnSrdnnyZYwh[XO|YYm= M3TsbFUxOCC3TR?= MnnvRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjD2bZJidCCrbn\lZ5Rqfmm2eTDheEA2ODBidV2gbY5kfWKjdHXkJIZweiB2IHjyd{BxemmxcjD0c{B3cXKjbDDpcoZm[3Srb36gcYVie3W{ZXSgZZQhPzJiaILzJJBwe3RiaX7m[YN1cW:wIHL5JIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?= M3PXVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI MmfBSpVv[3Srb36gZZN{[Xl? NVfrUngxOC53IH3N NV\RVXRuOiCqcoO= M2j3V2lv[3KnYYPlJIlvKDVvYYrhMYREXFBxZFPUVEBz[XSrbzDpckBpfW2jbjDVN|c{NU2DR1mgZ4VtdHNiYYSgNE42KG2PIIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliNT3hfoEuSyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBNSy2PUz;NV{BidmGueYPpd{Bz\WyjdHn2[UB1dyB3LXH6ZU1E NEHQTWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
U373-MAGI MVnGeY5kfGmxbjDhd5NigQ>? M4XuVVIhdU1? MWW2JIhzew>? M1G4ZXJm\HWldHnvckBqdiCmQWTQJIxmfmWuIHnuJIh2dWGwIGWzO|MuVUGJSTDj[YxteyCjdDCyJI1OKGGodHXyJFYhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nz NInLeWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
U373-MAGI NWXjVmM4TnWwY4Tpc44h[XO|YYm= NYDqcVFXOC53IH3N MVOyJIhzew>? MV\S[YR2[3Srb36gbY4h\EOWUDDs[ZZmdCCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XRiMD61JI1OKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2jenGtR{Bi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC0JIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrcx?= MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI NXz5R3Q3TnWwY4Tpc44h[XO|YYm= NGf1[mMzKG2P NY\Ed4t{OiCqcoO= NGXaZYNT\WS3Y4Tpc44hcW5iZFPUVEBt\X[nbDDpckBpfW2jbjDVN|c{NU2DR1mgZ4VtdHNiYYSgNkBuVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMWMh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgUGMuVVNxTWOgZY5idHm|aYOgdoVt[XSrdnWgeI8hPS2jenGtRy=> MlTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI MlrtSpVv[3Srb36gZZN{[Xl? MVGwMlUhdU1? M{LRSlIhcHK| MXrJcoNz\WG|ZTDpckA2NWG8YT3kR3RRN2SFVGCgdoF1cW9iaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IECuOUBuVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE NXjhT5lCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI NWHxZYl4TnWwY4Tpc44h[XO|YYm= MViyJI1O NVTDTY5NOiCqcoO= M3m5[mlv[3KnYYPlJIlvKDVvYYrhMYREXFBxZFPUVEBz[XSrbzDpckBpfW2jbjDVN|c{NU2DR1mgZ4VtdHNiYYSgNkBuVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE NXTkc3dWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI MX7GeY5kfGmxbjDhd5NigQ>? M4jpVVAvPSCvTR?= M17kSFIhcHK| NYn5dnZzWmWmdXP0bY9vKGmwIHTDWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy|IHH0JFAvPSCvTTDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IEWtZZpiNWSFIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRiaILzJIJ6KEyFLV3TM21UKGGwYXz5d4l{KHKnbHH0bZZmKHSxIEWtZZpiNWSF M3v5c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI NX20dll7TnWwY4Tpc44h[XO|YYm= MWiyJI1O NXz4fJUzOiCqcoO= M4HscnJm\HWldHnvckBqdiCmQ2TQJIxmfmWuIHnuJIh2dWGwIGWzO|MuVUGJSTDj[YxteyCjdDCyJI1OKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2jenGt[GMh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgUGMuVVNxTWOgZY5idHm|aYOgdoVt[XSrdnWgeI8hPS2jenGt[GM> NYr6NFJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
TC32 M4\3d5FJXFNiYYPzZZk> MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? MlLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MlrpdWhVWyCjc4PhfS=> M4\ZRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| M3Lwd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 NGfBcYZyUFSVIHHzd4F6 MlTmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NEXSemxyUFSVIHHzd4F6 NGHjeFRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NGTEZ41yUFSVIHHzd4F6 MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> NW\ZNndSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NFjpfIRyUFSVIHHzd4F6 M33kV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= M{TMS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MnLKdWhVWyCjc4PhfS=> Ml3JdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NHfKWpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MmrmdWhVWyCjc4PhfS=> M{D6d5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MnzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MkHsdWhVWyCjc4PhfS=> MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NU\FOFRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NWDzVo1neUiWUzDhd5NigQ>? MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> NXrtS5o4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS NXTPUplHeUiWUzDhd5NigQ>? NEO3Vo9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN? NUHxV2RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NX\NZmJreUiWUzDhd5NigQ>? NXjFdYxxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NHLDOYRyUFSVIHHzd4F6 MmG4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= M1rO[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 Mo\YdWhVWyCjc4PhfS=> M4jKVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NG\MRpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NEXzd5pyUFSVIHHzd4F6 M2TLOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

Protocol (from reference)

Cell Research:[3]
  • Cell lines: Erythroid cells
  • Concentrations: 30 μM
  • Incubation Time: 96 h
  • Method: Erythroid cells obtained from peripheral blood of the same patients(Thirteen β-Thal/HbE patients are treated with hydroxyurea orally for 2 years at a starting dose of 5 mg/kg/day for 5 days/week with escalation to a maximum of 10 mg/kg/day) 1 year after they had stopped hydroxyurea treatment are treated with hydroxyurea in vitro.Treatment of cells performs in primary culture with 30 μM hydroxyurea for 96 hours.
Animal Research:[4]
  • Animal Models: Female athymic (nu/nu) nude mice(used for xenograft model)
  • Dosages: 1500 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 76.05
Formula

CH4N2O2

CAS No. 127-07-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C(=O)(N)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05434000 Recruiting Drug: Hydroxyurea Sickle Cell Disease|Stroke Barau Dikko Teaching Hospital November 6 2021 Not Applicable
NCT04808778 Active not recruiting Drug: Hydroxyurea therapy per standard care Sickle Cell Disease|Sickle Cell Anemia|Stroke Ischemic|Silent Stroke|Silent Cerebral Infarct|Stroke Vanderbilt University Medical Center|Aminu Kano Teaching Hospital May 17 2021 --
NCT04750707 Active not recruiting Drug: Hydroxyurea Sickle Cell Anemia in Children Global Health Uganda LTD|Columbia University|University of Pittsburgh|Emory University|Mulago Hospital Uganda|Makerere University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) March 9 2021 Phase 3
NCT04691323 Recruiting Other: HU-Go app Sickle Cell Disease|Sickle B+ Thalassemia|Sickle Beta Zero Thalassemia|Sickle Cell Hemoglobin C Ann & Robert H Lurie Children''s Hospital of Chicago|National Heart Lung and Blood Institute (NHLBI) March 2 2021 Not Applicable
NCT05476562 Completed Other: Tyrosine Kinase Inhibitors (TKIs) Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis March 8 2021 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Hydroxyurea (NSC-32065) | Hydroxyurea (NSC-32065) supplier | purchase Hydroxyurea (NSC-32065) | Hydroxyurea (NSC-32065) cost | Hydroxyurea (NSC-32065) manufacturer | order Hydroxyurea (NSC-32065) | Hydroxyurea (NSC-32065) distributor